CONSUMERS BANCORP INC /OH/ (CBKM): Results of Operations and Financial Condition

CONSUMERS BANCORP INC /OH/ (CBKM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Consumers Bancorp, Inc. Reports: ● Net income increased by $404 thousand, or 15.3%, to $3.0 million for the three-month period ended September 30, 2026 compared with the same period last year. ● Net interest income increased by $1.2 million, or 12.9%, for the three-m

Original reporting
Published Oct 21, 2026, 3:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CBKM
Bullish
medium confidence
Mentioned
$CBKM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CBKMBullishMed
01

Why it matters

The earnings release provides fresh data for traders; the modest beat and strong loan growth could prompt a short‑term rally, but the micro‑cap size limits broader market impact.

02

Market read

Primary earnings disclosure for a micro‑cap regional bank; modest upside potential but limited overall market relevance.

03

What to watch

Potential future headwinds from inflation and rate volatility could dampen loan demand.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Consumers Bancorp (OTCQX: CBKM) filed a Form 8‑K reporting its quarterly results, highlighting net income growth, loan and deposit expansion, and low charge‑off rates.

Company-level read

Ticker impact

$CBKMBullishMedium confidence
Context

Consumers Bancorp reported Q1 FY2027 earnings with net income of $3.0M, a 15.3% YoY increase, and loan and deposit growth.

Expected impact

likely modest upside as market prices in earnings beat and loan growth

Evidence & confidence

Revenue and loan expansion exceed prior year, but absolute numbers are small for a micro‑cap; price move expected to be limited.

Market effects

Positive signal for regional community banks showing loan growth despite higher rates.

May boost sentiment for Ohio‑based financial stocks.

Limited to niche banking sector.

Counterpoint

Small earnings beat may be outweighed by higher interest‑rate environment and rising cost pressures.

Key entities

  • Ralph J. Lober II

    President and CEO who commented on growth and future expansion.

Related articles

$CBKMMed

CONSUMERS BANCORP INC /OH/ (CBKM): Results of Operations and Financial Condition

CONSUMERS BANCORP INC /OH/ (CBKM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Consumers Bancorp, Inc. Reports: ● Net income increased by $665 thousand, or 29.0%, for the three-month period and by $2.5 million, or 28.8%, for twelve-month period ended June 30, 2026, compared with the same periods last year. ● Net interest income increased by $1.

$MRCYMed

Mercury Systems 3Q 2026: Revenue $253.15M, EPS $0.21 — 10-Q Summary

Mercury Systems reported 3Q 2026 revenue of $253.15M, up 12.4% YoY, and net income of $13.09M, reversing a prior-year loss. Growth in radar and electronic warfare applications drove results, while C4I revenue declined. Gross margin improved to 35.2% from 27.9%. The company expects to recognize 46% of its $1.193B remaining performance obligations as revenue in the next 12 months.

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$ATROHighAI 8/10

Astronics shares tumble on soft fourth quarter revenue outlook

Astronics (ATRO) reported Q3 earnings of $1.08 per share, beating estimates, with revenue up 28.5% YoY to $271.7M. However, shares fell 11% on Q4 revenue guidance of $255M-$275M, below expectations. The company maintained its full-year 2026 revenue guidance. Aerospace segment sales hit a record $245.5M, with strong demand in inflight entertainment and connectivity.